Literature DB >> 18854445

CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis.

S Zelasko1, M Hollingshead, M Castillo, T W Bouldin.   

Abstract

We present a patient with progressive dural calcifications, thickening, and enhancement presumably related to the development of nephrogenic systemic fibrosis (NSF). Head CT demonstrated progressive dural calcifications, whereas MR imaging demonstrated progressive dural thickening and enhancement during a 3-year period in which the patient received several gadolinium-enhanced MR imaging studies. To the best of our knowledge, dural calcifications are the only described intracranial finding of NSF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854445      PMCID: PMC8118947          DOI: 10.3174/ajnr.A1225

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  12 in total

1.  Nephrogenic fibrosing dermopathy with involvement of the dura mater.

Authors:  Adam Saenz; Rajni Mandal; Richard Kradin; E Tessa Hedley-Whyte
Journal:  Virchows Arch       Date:  2006-08-02       Impact factor: 4.064

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

Authors:  Dale R Broome; Mark S Girguis; Pedro W Baron; Alfred C Cottrell; Ingrid Kjellin; Gerald A Kirk
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

4.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure.

Authors:  Cynthia Kucher; Joanna Steere; Rosalie Elenitsas; Don L Siegel; Xiaowei Xu
Journal:  J Am Acad Dermatol       Date:  2006-02       Impact factor: 11.527

5.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

6.  Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature.

Authors:  Sarah E Gibson; Carol F Farver; Richard A Prayson
Journal:  Arch Pathol Lab Med       Date:  2006-02       Impact factor: 5.534

7.  Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis.

Authors:  Henry F Krous; Eric Breisch; Amy E Chadwick; Lee Pinckney; Denise M Malicki; Nadine Benador
Journal:  Pediatr Dev Pathol       Date:  2007 Sep-Oct

Review 8.  Nephrogenic systemic fibrosis: early recognition and treatment.

Authors:  Eleanor A Knopp; Shawn E Cowper
Journal:  Semin Dial       Date:  2008-01-23       Impact factor: 3.455

9.  Tentorial and dural calcification with tertiary hyperparathyroidism: a rare entity in chronic renal failure.

Authors:  U Dorenbeck; T Leingärtner; T Bretschneider; B K Krämer; S Feuerbach
Journal:  Eur Radiol       Date:  2002-05-09       Impact factor: 5.315

Review 10.  Clinical and histological findings in nephrogenic systemic fibrosis.

Authors:  Shawn E Cowper; Morgan Rabach; Michael Girardi
Journal:  Eur J Radiol       Date:  2008-03-05       Impact factor: 3.528

View more
  3 in total

1.  Prevalence of and Factors Associated with Dural Thickness in Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Authors:  Adnan I Qureshi; Iryna Lobanova; Naseeb Ullah; Amna Sohail; Taqi A Zafar; Adil M Malik; Mushtaq H Qureshi
Journal:  J Vasc Interv Neurol       Date:  2015-07

Review 2.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

3.  Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.

Authors:  Zhitong Zou; Lin Ma
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.